Y-mAbs(US:YMAB) ZACKSยท2025-07-24 17:00Core Viewpoint - Y-mAbs Therapeutics, Inc. (YMAB) has received an upgrade to a Zacks Rank 2 (Buy), indicating a positive outlook based on rising earnings estimates, which significantly influence stock prices [1][4][6]. Earnings Estimates and Stock Ratings - The Zacks rating system is primarily driven by changes in a company's earnings picture, with the Zacks Consensus Estimate reflecting EPS estimates from sell-side analysts [2][3]. - The Zacks Rank stock-rating system categorizes stocks into five groups based on earnings estimates, with a strong historical performance, particularly Zacks Rank 1 stocks averaging a +25% annual return since 1988 [8][10]. Recent Performance of Y-mAbs Therapeutics - Y-mAbs Therapeutics is projected to earn -$0.97 per share for the fiscal year ending December 2025, showing no year-over-year change, but the Zacks Consensus Estimate has increased by 5.1% over the past three months [9]. - The upgrade to Zacks Rank 2 places Y-mAbs in the top 20% of Zacks-covered stocks, indicating a strong potential for market-beating returns in the near term [11]. Influence of Institutional Investors - Changes in earnings estimates are closely correlated with stock price movements, influenced by institutional investors who adjust their valuations based on these estimates, leading to significant stock transactions [5].